Chardan Capital Increases Prime Medicine (NYSE:PRME) Price Target to $16.00
Prime Medicine (NYSE:PRME – Free Report) had its price target lifted by Chardan Capital from $15.00 to $16.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the stock. Several other research analysts have also recently weighed in on PRME. JMP Securities assumed coverage on shares of Prime Medicine […]
Prime Medicine (NYSE:PRME – Free Report) had its price target lifted by Chardan Capital from $15.00 to $16.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the stock. Several other research analysts have also recently weighed in on PRME. JMP Securities assumed coverage on shares of Prime Medicine […]
